The renin–angiotensin system: a possible new target for depression

BMC Medicine

Review

Brisa S. Fernandes¹  Michael Berk²  Sung-Wan Kim³  Brendon Stubbs⁴  Victor Chavarria⁵  Círia Pereira⁶  João Vian⁶  João Quevedo⁷  André F. Carvalho⁸  Cristiano Köhler⁸ 

[1] Deakin University, IMPACT Strategic Research Centre, School of Medicine, University Hospital Geelong, Barwon Health, Geelong, VIC, Australia;Deakin University, IMPACT Strategic Research Centre, School of Medicine, University Hospital Geelong, Barwon Health, Geelong, VIC, Australia;Department of Psychiatry, Orygen the National Centre of Excellence for Youth Mental Health and Orygen Research Centre, and the Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia;Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea;Health, Social Care and Education, Anglia Ruskin University, Chelmsford, UK;Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, UK;Institute of clinical Research and Education in Medicine (IREM), Padova, Italy;Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, SE5 8AZ, London, UK;Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar (PSM), Barcelona, Spain;Psychiatry and Mental Health Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal;Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal;Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA;Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA;Neuroscience Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA;Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina (UNESC), Criciúma, SC, Brazil;Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil;

关键词: Depression;    Psychiatry;    Inflammation;    Renin–angiotensin system;    Angiotensin;    ATR1;    ATR2;    Mas;    Angiotensin receptor blockers;    Angiotensin-converting enzyme inhibitors;   

DOI  :  10.1186/s12916-017-0916-3

 received in 2017-03-29, accepted in 2017-07-18,  发布年份 2017

来源: Springer

【 摘 要 】

Depression remains a debilitating condition with an uncertain aetiology. Recently, attention has been given to the renin–angiotensin system. In the central nervous system, angiotensin II may be important in multiple pathways related to neurodevelopment and regulation of the stress response. Studies of drugs targeting the renin–angiotensin system have yielded promising results. Here, we review the potential beneficial effects of angiotensin blockers in depression and their mechanisms of action. Drugs blocking the angiotensin system have efficacy in several animal models of depression. While no randomised clinical trials were found, case reports and observational studies showed that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers had positive effects on depression, whereas other antihypertensive agents did not. Drugs targeting the renin–angiotensin system act on inflammatory pathways implicated in depression. Both preclinical and clinical data suggest that these drugs possess antidepressant properties. In light of these results, angiotensin system-blocking agents offer new horizons in mood disorder treatment.

【 授权许可】

CC BY   
© The Author(s). 2017